미국 · 보도자료 · Acurx Pharmaceuticals, Inc. · 2026-09-29 12:01
다제재발성 C.디피실 임상서 이베자폴스타트 첫 환자 등록
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has...
